In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthovita: The Most Natural Thing

Executive Summary

The spinal orthopedics business, long focused on traditional fixation tools such as screws, dowels, cements, and more recently, interbody fusion cages, has been undergoing a slow evolution that also incorporates a biological approach to bone healing. Orthovita believes its glass/resin-based bioactive materials mimic the biology of bone healing better than previous synthetics, and that these materials can more easily incorporate biologic agents for an added bone-healing boost. Now the company faces the challenge of generating the data that will differentiate it from a host of competitors making similar claims and enable it to penetrate a market inherently slow to adopt new technology.

You may also be interested in...



Has Orthovita's Fight Finally Ended?

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.

Has Orthovita's Fight Finally Ended?

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.

Scaffolds in Tissue Engineering

Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel